{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:09:16Z","timestamp":1773860956758,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.cllc.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:29:59Z","timestamp":1628548199000},"page":"e43-e53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre"],"prefix":"10.1016","volume":"23","author":[{"given":"Sabine","family":"Schmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaleeq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-1901","authenticated-orcid":false,"given":"Maisha","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devalben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Zaeimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Donahoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-3396","authenticated-orcid":false,"given":"Byoung Chun John","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2021.08.003_bib0001","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"issue":"Suppl 1","key":"10.1016\/j.cllc.2021.08.003_bib0002","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.lungcan.2005.03.015","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: The Memorial Sloan-Kettering experience","volume":"49","author":"Flores","year":"2005","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2021.08.003_bib0003","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2021.08.003_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/icvts\/ivs542","article-title":"What is the survival after surgery for localized malignant pleural mesothelioma?","volume":"16","author":"Gelvez-Zapata","year":"2013","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"10.1016\/j.cllc.2021.08.003_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.cllc.2021.08.003_bib0006","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10026","key":"10.1016\/j.cllc.2021.08.003_bib0007","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cllc.2021.08.003_bib0008","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"issue":"2-3","key":"10.1016\/j.cllc.2021.08.003_bib0009","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.cllc.2021.08.003_bib0010","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2021.08.003_bib0011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2021.08.003_bib0012","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2021.08.003_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2021.08.003_bib0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.cllc.2021.08.003_bib0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2021.08.003_bib0016","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"12","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2021.08.003_bib0017","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10272","key":"10.1016\/j.cllc.2021.08.003_bib0018","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.cllc.2021.08.003_bib0019","article-title":"Abstract PS01.11: Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from the CONFIRM phase 3 trial","volume":"2021","author":"Fennell","year":"2020","journal-title":"WCLC"},{"key":"10.1016\/j.cllc.2021.08.003_bib0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.lungcan.2018.10.009","article-title":"Real-life treatment practice for malignant pleural mesothelioma in Belgium","volume":"125","author":"Rosskamp","year":"2018","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2021.08.003_bib0021","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2015.05.014","article-title":"Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England","volume":"89","author":"Damhuis","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2021.08.003_bib0022","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): Final results from a single-centre, phase 2 trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.cllc.2021.08.003_bib0023","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/cncr.29386","article-title":"Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?","volume":"121","author":"Sacher","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2021.08.003_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejon.2016.09.007","article-title":"A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer","volume":"25","author":"Ball","year":"2016","journal-title":"Eur J Oncol Nurs"},{"issue":"28","key":"10.1016\/j.cllc.2021.08.003_bib0025","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2021.08.003_bib0026","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1634\/theoncologist.2018-0501","article-title":"Systemic therapy use and outcomes after relapse from preoperative radiation and extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"24","author":"Soldera","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.cllc.2021.08.003_bib0027","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jgo.2019.02.013","article-title":"Patterns of care and survival of older patients with malignant pleural mesothelioma","volume":"10","author":"Linton","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2021.08.003_bib0028","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1245\/s10434-019-07351-6","article-title":"Management of malignant pleural mesothelioma in the elderly population","volume":"26","author":"Verma","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2021.08.003_bib0029","first-page":"32714","article-title":"First-line nivolumab+ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743","volume":"20","author":"Baas","year":"2020","journal-title":"WCLC"},{"issue":"3","key":"10.1016\/j.cllc.2021.08.003_bib0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: A systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2021.08.003_bib0031","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.cllc.2021.08.003_bib0032","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.cllc.2021.08.003_bib0033","first-page":"8507","article-title":"Abstract 8507: A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"ASCO"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421002072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421002072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:11:41Z","timestamp":1761505901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730421002072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1525730421002072"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.08.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}